Exploration of the mutational landscape of cutaneous leiomyoma confirms FH as a driver gene and identifies targeting purine metabolism as a potential therapeutic strategy
Br J Dermatol. 2024 Nov 7:ljae432.
doi: 10.1093/bjd/ljae432.
Online ahead of print.
1 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
2 Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
3 Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
4 Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
5 Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
6 Institute of Pathology, School of Medicine and Health, Technical University Munich, Munich, Germany.
7 Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
8 Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
9 Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
10 Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, MI, USA.
11 University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute for Metabolomics in Ageing, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany.
12 University of Cologne, Faculty of Mathematics and Natural Sciences, Institute of Genetics, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany.
13 University of Edinburgh, Division of Pathology, Centre for Comparative Pathology, CRUK Edinburgh Centre, Institute of Genetics and Cancer, Western General Hospital, Crewe Road South, Edinburgh, U.K.